Viking Q3 Loss Widens to $183M as Obesity Phase 3 Spend Ramps; $960M Cash
VKTX is trading near its 52-week low of $23.82 (6.7% above the low).
Summary
Viking's Q3 net loss widened to $183.2M ($1.55/share) from $90.8M a year ago, driven by R&D jumping to $166.8M from $90.0M as multiple late-stage obesity trials run in parallel. Cash, equivalents and short-term investments stood at $960M, which covers the Phase 3 build-out and pre-launch work without an immediate return to the capital markets. The company started the oral VK2735 SUNRISE Phase 3 program while the subcutaneous VANQUISH Phase 3 trials continue, and VK3019's single-ascending-dose study is nearing completion with a multiple-ascending-dose start targeted for Q1 2027. The loss is largely the expected cost of running both formulations through late-stage development, and the balance sheet is the key offset. This follows the September concurrent upsized stock and convertible notes offerings, which raised about $575.0 million in gross proceeds and roughly $550 million in net proceeds, and is what funds the current burn. The real swing factor remains the VANQUISH and SUNRISE Phase 3 efficacy and safety readouts, which will determine approval and launch timing.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Viking's September concurrent upsized stock and convertible notes offerings raised about $575.0 million in gross proceeds, with roughly $550 million in net proceeds.
At the time of this announcement, VKTX was trading at $25.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $23.82 to $43.15. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.